At 7 years, the cPFS rate was 67.2% without cabazitaxel and 62.8% with cabazitaxel, indicating no significant effect of cabazitaxel on cPFS (adjusted hazard ratio [aHR], 1.09; 95% CI, 0.85-1.38; P ...
Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of ...
Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage. This is an ASCO Meeting Abstract ...
Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Morning Overview on MSN
Experimental prostate cancer drug shrinks tumors in early clinical trial
Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...
Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of ...
Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...
As reports surface that the UK’s national screening committee are set to reject proposals for any national prostate screening programme, experts warn that the decision, if followed through with, puts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results